OBJECTIVES: Aim of the present study was to evaluate whether an ACE inhibitor intervention is able to significantly improve physical performance and muscle strength in a sample of older persons. DESIGN: Double-blind, cross-over, randomized, placebo-controlled trial. SETTING: The Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. PARTICIPANTS: Participants were 257 subjects aged 55 years and older with high cardiovascular risk profile. INTERVENTION: Six months of fosinopril use versus placebo. MEASUREMENTS: The Short Physical Performance Battery score (rescaled to obtain a continuous variable ranging from 0 to 3 points), and the hand grip strength were measured at the baseline visit, and after 6 and 12 months of follow-up. Paired t test analyses were performed to compare results of physical function measures after ACE inhibition and placebo interventions. RESULTS:Mean age of the sample population was 65.97 (standard deviation 7.41) years old. No statistically significant difference was found at the Short Physical Performance Battery (P=.23) and hand grip strength (P=.57) results after ACE inhibition (2.113, standard deviation [SD] 0.284; and 37.044 kg, SD 12.993 kg, respectively) compared to placebo (2.096, SD 0.298; and 36.898 kg, SD 13.178 kg, respectively). No significant effects from ACE inhibition were also found when the 3 subtests composing the Short Physical Performance Battery (ie, 4-meter walking speed, balance, and chair stand tests) were separately analyzed. Consistent negative results were obtained after analyses were restricted to participants showing the highest compliance to treatment and/or receiving the maximum fosinopril dosage. CONCLUSION: No significant modifications in physical performance and muscle strength were reported after 6 months of fosinopril use in older persons with high cardiovascular risk profile. Given these negative findings, it is possible that the beneficial effects of ACE inhibitors on physical function might be attributable to the activation of a virtuous cycle determined by an improved cardiovascular system. Further specifically designed studies are needed to confirm our findings, and expand them to different populations and ACE inhibitors. If our findings will be confirmed, the extracardiovascular properties of ACE inhibitors in older persons might be substantially resized. Copyright (c) 2010 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVES: Aim of the present study was to evaluate whether an ACE inhibitor intervention is able to significantly improve physical performance and muscle strength in a sample of older persons. DESIGN: Double-blind, cross-over, randomized, placebo-controlled trial. SETTING: The Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. PARTICIPANTS: Participants were 257 subjects aged 55 years and older with high cardiovascular risk profile. INTERVENTION: Six months of fosinopril use versus placebo. MEASUREMENTS: The Short Physical Performance Battery score (rescaled to obtain a continuous variable ranging from 0 to 3 points), and the hand grip strength were measured at the baseline visit, and after 6 and 12 months of follow-up. Paired t test analyses were performed to compare results of physical function measures after ACE inhibition and placebo interventions. RESULTS: Mean age of the sample population was 65.97 (standard deviation 7.41) years old. No statistically significant difference was found at the Short Physical Performance Battery (P=.23) and hand grip strength (P=.57) results after ACE inhibition (2.113, standard deviation [SD] 0.284; and 37.044 kg, SD 12.993 kg, respectively) compared to placebo (2.096, SD 0.298; and 36.898 kg, SD 13.178 kg, respectively). No significant effects from ACE inhibition were also found when the 3 subtests composing the Short Physical Performance Battery (ie, 4-meter walking speed, balance, and chair stand tests) were separately analyzed. Consistent negative results were obtained after analyses were restricted to participants showing the highest compliance to treatment and/or receiving the maximum fosinopril dosage. CONCLUSION: No significant modifications in physical performance and muscle strength were reported after 6 months of fosinopril use in older persons with high cardiovascular risk profile. Given these negative findings, it is possible that the beneficial effects of ACE inhibitors on physical function might be attributable to the activation of a virtuous cycle determined by an improved cardiovascular system. Further specifically designed studies are needed to confirm our findings, and expand them to different populations and ACE inhibitors. If our findings will be confirmed, the extracardiovascular properties of ACE inhibitors in older persons might be substantially resized. Copyright (c) 2010 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.
Authors: Marco Pahor; Steven N Blair; Mark Espeland; Roger Fielding; Thomas M Gill; Jack M Guralnik; Evan C Hadley; Abby C King; Stephen B Kritchevsky; Cinzia Maraldi; Michael E Miller; Anne B Newman; Walter J Rejeski; Sergei Romashkan; Stephanie Studenski Journal: J Gerontol A Biol Sci Med Sci Date: 2006-11 Impact factor: 6.053
Authors: M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan Journal: Circulation Date: 1992-08 Impact factor: 29.690
Authors: Christy S Carter; Matteo Cesari; Walter T Ambrosius; Nan Hu; Debra Diz; Sherry Oden; William E Sonntag; Marco Pahor Journal: J Gerontol A Biol Sci Med Sci Date: 2004-05 Impact factor: 6.053
Authors: Matteo Cesari; Brenda W J H Penninx; Marco Pahor; Fulvio Lauretani; Anna Maria Corsi; G Rhys Williams; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Thomas W Buford; Todd M Manini; Fang-Chi Hsu; Matteo Cesari; Stephen D Anton; Susan Nayfield; Randall S Stafford; Timothy S Church; Marco Pahor; Christy S Carter Journal: J Am Geriatr Soc Date: 2012-06-21 Impact factor: 5.562
Authors: Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor Journal: Ageing Res Rev Date: 2015-10-14 Impact factor: 10.895
Authors: Thomas W Buford; Michael E Miller; Timothy S Church; Thomas M Gill; Rebecca Henderson; Fang-Chi Hsu; Mary M McDermott; Neelesh Nadkarni; Marco Pahor; Randall S Stafford; Christy S Carter Journal: J Gerontol A Biol Sci Med Sci Date: 2016-02-10 Impact factor: 6.053